抗PD-1/PD-L1疗法致免疫相关不良反应机制及预测标志物的研究进展

Progress in mechanisms and biomarkers of immune-related adverse events induced by anti-PD-1/PD-L1

抗程序性细胞死亡受体-1(programmed cell death protein-1,PD-1)和抗程序性死亡受体配体-1(programmed cell death ligand-1,PD-L1)是目前广泛使用的免疫检查点抑制剂,在肿瘤免疫治疗方面取得了巨大的成就,但同时也导致免疫相关不良反应(immune-related adverse events,irAEs),严重者甚至会导致患者死亡。因此,明确irAEs的发生机制,提早预测irAEs非常重要。本文由细胞、免疫系统、个体水平层面对抗PD-1/PD-L1疗法致irAEs的发生机制进行了总结,并从一般临床特征、免疫细胞因素、细胞因子相关、基因表达结果等方面汇总了irAEs的预测指标。

PD-1/PD-L1 antibody is a widespread used immune checkpoint inhibitor in tumor immunotherapy,which has made great achievements,but it also leads to irAEs,which can even lead to patient death in severe cases.Therefore,it is important to clarify the mechanism and early prediction of irAEs.In this paper,we summarize the pathogenic mechanisms of irAEs by the cell,immune system and individual level and sum up its risk factors and biomarkers.